Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain
associated with vertebral fracture.
Secondary objectives were:
- to assess the safety and tolerability of REGN475/SAR164877 in patients with vertebral
fracture pain;
- to characterize the pharmacokinetic and immunogenicity profiles of REGN475/SAR164877 in
this population.